牛牛AI助手已提取核心信息
iBio Inc, a biotechnology company based in Bryan, Texas, has announced a significant change in its financial oversight structure. On February 15, 2024, the company's Audit Committee initiated a competitive process to select a new independent registered public accounting firm for the fiscal year ending June 30, 2024. This process led to the engagement of Grassi & Co., CPAs, P.C. as the new auditor, with the formal engagement beginning on February 20, 2024. The change comes after the resignation of the previous auditor, CohnReznick LLP, which occurred on the same day as the initiation of the search for their replacement. CohnReznick's resignation was not due to any disagreements on accounting principles or practices, financial statement disclosure, or auditing scope or procedure. However, it is...Show More
iBio Inc, a biotechnology company based in Bryan, Texas, has announced a significant change in its financial oversight structure. On February 15, 2024, the company's Audit Committee initiated a competitive process to select a new independent registered public accounting firm for the fiscal year ending June 30, 2024. This process led to the engagement of Grassi & Co., CPAs, P.C. as the new auditor, with the formal engagement beginning on February 20, 2024. The change comes after the resignation of the previous auditor, CohnReznick LLP, which occurred on the same day as the initiation of the search for their replacement. CohnReznick's resignation was not due to any disagreements on accounting principles or practices, financial statement disclosure, or auditing scope or procedure. However, it is noted that the company's financial statements for the fiscal year ended June 30, 2023, included an explanatory paragraph regarding the company's ability to continue as a going concern. Additionally, a material weakness in controls related to accounting for stock-based compensation expense was identified and subsequently remediated in the same fiscal year. iBio Inc has filed the required letter from CohnReznick with the SEC, confirming their agreement with the statements made by the company regarding their resignation.
总部位于德克萨斯州布莱恩的生物技术公司iBio Inc宣布其财务监督结构发生重大变化。2024年2月15日，该公司的审计委员会启动了竞争程序，为截至2024年6月30日的财政年度选择一家新的独立注册会计师事务所。这一过程促使Grassi & Co.、CPA、P.C. 被聘为新的审计师，正式聘用将于2024年2月20日开始。这一变化是在前任审计师CohnrezNick LLP辞职之后发生的，辞职发生在开始寻找接班人的同一天。CohnrezNick的辞职不是因为在会计原则或惯例、财务报表披露或审计范围或程序上存在任何分歧。但是，值得注意的是，该公司截至2023年6月30日的财年财务报表中有一段关于公司继续经营能力的解释性段落。此外，在与股票薪酬支出会计相关的控制措施中发现了一个重大缺陷，随后在同一财年进行了补救。iBio Inc已向美国证券交易委员会提交了CohnrezNick的必要信函，确认他们同意该公司就其辞职发表的声明。
总部位于德克萨斯州布莱恩的生物技术公司iBio Inc宣布其财务监督结构发生重大变化。2024年2月15日，该公司的审计委员会启动了竞争程序，为截至2024年6月30日的财政年度选择一家新的独立注册会计师事务所。这一过程促使Grassi & Co.、CPA、P.C. 被聘为新的审计师，正式聘用将于2024年2月20日开始。这一变化是在前任审计师CohnrezNick LLP辞职之后发生的，辞职发生在开始寻找接班人的同一天。CohnrezNick的辞职不是因为在会计原则或惯例、财务报表披露或审计范围或程序上存在任何分歧。但是，值得注意的是，该公司截至2023年6月30日的财年财务报表中有一段关于公司继续经营能力的解释性段落。此外，在与股票薪酬支出会计相关的控制措施中发现了一个重大缺陷，随后在同一财年进行了补救。iBio Inc已向美国证券交易委员会提交了CohnrezNick的必要信函，确认他们同意该公司就其辞职发表的声明。
有用
没用
